MARKET

AIM

AIM

AIM ImmunoTech Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

1.970
-0.100
-4.83%
Pre Market: 2.010 +0.04 +2.03% 04:21 09/23 EDT
OPEN
2.060
PREV CLOSE
2.070
HIGH
2.060
LOW
1.970
VOLUME
23
TURNOVER
--
52 WEEK HIGH
3.060
52 WEEK LOW
1.650
MARKET CAP
94.26M
P/E (TTM)
-5.1530
1D
5D
1M
3M
1Y
5Y
BRIEF-AIM ImmunoTech Says Ellen Lintal To Retire As CFO
reuters.com · 1d ago
AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients
Benzinga · 1d ago
BRIEF-AIM Immunotech Announces Positive Progress On Requested FDA Meeting For Proposed Ampligen Clinical Trial In Post-Covid-19 Cognitive Dysfunction
reuters.com · 1d ago
AIM ImmunoTech Says FDA Meeting Request Has Been Deemed Sufficient For Transfer To FDA's Division Of Neurology
AIM ImmunoTech Inc. (NYSE:AIM) today announced positive progress with the company's meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as an infusion
Benzinga · 1d ago
AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction
OCALA, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company’s meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as ...
GlobeNewswire · 1d ago
AIM ImmunoTech FDA Meeting Request for Ampligen Study Transferred to Neurology Division; Shares Rise Pre-Bell
MT Newswires · 2d ago
BRIEF-Aim Immunotech Provides An Update On Its Pending Phase 2A Human Challenge Trial Using Its Drug Ampligen
reuters.com · 2d ago
AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen
AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus (HRV-16, a common cold virus) an...
GlobeNewswire · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AIM. Analyze the recent business situations of AIM ImmunoTech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AIM stock price target is 6.67 with a high estimate of 8.50 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 93.54K
% Owned: 0.20%
Shares Outstanding: 47.85M
TypeInstitutionsShares
Increased
6
31
New
4
70.90K
Decreased
2
2.90K
Sold Out
7
13.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.30%
Pharmaceuticals & Medical Research
-0.11%
Key Executives
Chairman/Director
William Mitchell
President/Chief Executive Officer/Vice Chairman/General Counsel/Secretary/Director
Thomas Equels
Chief Financial Officer
Ellen Lintal
Chief Operating Officer/General Counsel/Secretary
Peter Rodino
Senior Vice President
Wayne Springate
Chief Scientific Officer
David Strayer
Director
Stewart Appelrouth
No Data
  • All
  • Financials
  • Insiders
More
About AIM
AIM ImmunoTech Inc. is a specialty pharmaceutical company. The Company focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is a drug which is also known as a new molecular entity that contains an active moiety. It is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen (rintatolimod), It is a drug of macromolecular RNA (ribonucleic acid) molecules, It is a sterile solution indicated for the treatment of severely debilitated patients with chronic fatigue syndrome (cfs) who have been diagnosed for longer than one year.

Webull offers kinds of AIM ImmunoTech Inc stock information, including AMEX:AIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIM stock methods without spending real money on the virtual paper trading platform.